| (D) pass an examination in nuclear pharmacy administered
by diplomates of the specialty board, that assesses knowledge and
competency in procurement, compounding, quality assurance, dispensing,
distribution, health and safety, radiation safety, provision of information
and consultation, monitoring patient outcomes, research and development;
or
(2) has completed:
(A) a 700-hour structured educational program, including
both:
(i) 200 hours of classroom and laboratory training
in the following areas:
(I) radiation physics and instrumentation;
(II) radiation protection;
(III) mathematics pertaining to the use and measurement
of radioactivity;
(IV) chemistry of radioactive material for medical
use; and
(V) radiation biology; and
(ii) supervised practical experience in a nuclear pharmacy
involving the following:
(I) shipping, receiving, and performing related radiation
surveys;
(II) using and performing checks for proper operation
of instruments used to determine the activity of dosages, survey meters,
and, if appropriate, instruments used to measure alpha- or beta-emitting
radionuclides;
(III) calculating, assaying, and safely preparing dosages
for patients or human research subjects;
(IV) using administrative controls to avoid medical
events in the administration of radioactive material; and
(V) using procedures to prevent or minimize radioactive
contamination and using proper decontamination procedures; and
(B) has obtained written attestation, signed by a preceptor
authorized nuclear pharmacist, that the individual has satisfactorily
completed the requirements in paragraph (2)(A) of this subsection
and is able to independently fulfill the radiation safety-related
duties as an authorized nuclear pharmacist.
(l) Training for experienced RSO, teletherapy or medical
physicist, authorized medical physicist, authorized user, nuclear
pharmacist, and authorized nuclear pharmacist.
(1) An individual identified on an agency, NRC, or
an agreement state license or a permit issued by the department, the
NRC, or an agreement state broad scope licensee or master material
license permit or by a master material license permittee of broad
scope as an RSO, a teletherapy or medical physicist, an authorized
medical physicist, a nuclear pharmacist or an authorized nuclear pharmacist
on or before January 14, 2019, need not comply with the training requirements
of subsections (h), (j), and (k) of this section, respectively, except
the RSO and authorized medical physicists identified in this paragraph
must meet the training requirements in subsections (h)(4) or (j)(3)
of this section, as appropriate, for any material or uses for which
they were not authorized before this date.
(2) Any individual certified by the American Board
of Health Physics in Comprehensive Health Physics; American Board
of Radiology; American Board of Nuclear Medicine; American Board of
Science in Nuclear Medicine; Board of Pharmaceutical Specialties in
Nuclear Pharmacy; American Board of Medical Physics in radiation oncology
physics; Royal College of Physicians and Surgeons of Canada in nuclear
medicine; American Osteopathic Board of Radiology; or American Osteopathic
Board of Nuclear Medicine on or before October 24, 2005, need not
comply with the training requirements of subsection (h) of this section
to be identified as an RSO or as an ARSO on an agency, NRC, or agreement
state license or NRC master material license permit for those materials
and uses that these individuals performed on or before October 24,
2005.
(3) Any individual certified by the American Board
of Radiology in therapeutic radiological physics, Roentgen ray and
gamma ray physics, xray and radium physics, or radiological physics,
or certified by the American Board of Medical Physics in radiation
oncology physics, on or before October 24, 2005, need not comply with
the training requirements for an authorized medical physicist described
in subsection (j) of this section, for those materials and uses that
these individuals performed on or before October 24, 2005.
(4) An RSO, a medical physicist, or a nuclear pharmacist,
who used only accelerator-produced radioactive materials, discrete
sources of radium-226, or both, for medical uses or in the practice
of nuclear pharmacy at a government agency or federally recognized
Indian Tribe before November 30, 2007, or at all other locations of
use before August 8, 2009, or an earlier date as noticed by the NRC,
need not comply with the training requirements of subsections (h),
(j) or (k) of this section, respectively, when performing the same
uses. A nuclear pharmacist, who prepared only radioactive drugs containing
accelerator-produced radioactive materials, or a medical physicist,
who used only accelerator-produced radioactive materials, at the locations
and during the time period identified in this paragraph, qualifies
as an authorized nuclear pharmacist or an authorized medical physicist,
respectively, for those materials and uses performed before these
dates, for the purposes of this chapter.
(5) An individual identified as a physician, dentist,
podiatrist or veterinarian authorized for the medical or veterinary
use of radioactive material.
(A) Physicians, dentists, or podiatrists identified
as authorized users for the medical use of radioactive material on
a license issued by the department, the NRC, or an agreement state,
a permit issued by an NRC master material licensee, a permit issued
by the department, the NRC, or an agreement state broad scope licensee,
or a permit issued by an NRC master material license broad scope permittee
on or before January 14, 2019, who perform only those medical uses
for which they were authorized on or before that date need not comply
with the training requirements of subsections (gg) through (ttt) of
this section.
(B) Physicians, dentists, or podiatrists not identified
as authorized users for the medical use of radioactive material on
a license issued by the department, the NRC, or an agreement state,
a permit issued by an NRC master material licensee, a permit issued
by the department, the NRC, or an agreement state broad scope licensee,
or a permit issued by an NRC master material license of broad scope
on or before October 24, 2005, need not comply with the training requirements
of subsections (gg) through (ttt) of this section for those materials
and uses that these individuals performed on or before October 24,
2005, as follows:
(i) For uses authorized under subsections (ff) or (hh)
of this section, or oral administration of sodium iodide I-131 requiring
a written directive for imaging and localization purposes, a physician
who was certified on or before October 24, 2005, in nuclear medicine
by the American Board of Nuclear Medicine; diagnostic radiology by
the American Board of Radiology; diagnostic radiology or radiology
by the American Osteopathic Board of Radiology; nuclear medicine by
the Royal College of Physicians and Surgeons of Canada; or American
Osteopathic Board of Nuclear Medicine in nuclear medicine;
(ii) For uses authorized under subsection (kk) of this
section, a physician who was certified on or before October 24, 2005,
by the American Board of Nuclear Medicine; the American Board of Radiology
in radiology, therapeutic radiology, or radiation oncology; nuclear
medicine by the Royal College of Physicians and Surgeons of Canada;
or the American Osteopathic Board of Radiology after 1984;
(iii) For uses authorized under subsections (rr) or
(ddd) of this section, a physician who was certified on or before
October 24, 2005, in radiology, therapeutic radiology or radiation
oncology by the American Board of Radiology; radiation oncology by
the American Osteopathic Board of Radiology; radiology, with specialization
in radiotherapy, as a British "Fellow of the Faculty of Radiology"
or "Fellow of the Royal College of Radiology"; or therapeutic radiology
by the Canadian Royal College of Physicians and Surgeons; and
(iv) For uses authorized under subsection (bbb) of
this section, a physician who was certified on or before October 24,
2005, in radiology, diagnostic radiology, therapeutic radiology, or
radiation oncology by the American Board of Radiology; nuclear medicine
by the American Board of Nuclear Medicine; diagnostic radiology or
radiology by the American Osteopathic Board of Radiology; or nuclear
medicine by the Royal College of Physicians and Surgeons of Canada.
(C) Physicians, dentists, or podiatrists who used only
accelerator-produced radioactive materials, discrete sources of radium-226,
or both, for medical uses performed at a government agency or federally
recognized Indian Tribe before November 30, 2007, or at all other
locations of use before August 8, 2009, or an earlier date as noticed
by the NRC, need not comply with the training requirements of subsections
(gg) through (ttt) of this section when performing the same medical
uses. A physician, dentist, or podiatrist, who used only accelerator-produced
radioactive materials, discrete sources of radium-226, or both, for
medical uses at the locations and time period identified Cont'd... |
